Adamas Pharmaceuticals Inc (NASDAQ:ADMS) saw unusually large options trading activity on Tuesday. Stock traders purchased 1,604 call options on the company. This represents an increase of 1,504% compared to the average volume of 100 call options.

A number of equities research analysts have issued reports on ADMS shares. Zacks Investment Research lowered shares of Adamas Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, January 5th. Noble Financial increased their target price on shares of Adamas Pharmaceuticals from $33.00 to $48.00 and gave the stock a “buy” rating in a report on Wednesday, November 8th. Needham & Company LLC reiterated a “buy” rating and set a $38.00 target price on shares of Adamas Pharmaceuticals in a report on Sunday, September 17th. ValuEngine lowered shares of Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, October 13th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and set a $30.00 target price on shares of Adamas Pharmaceuticals in a report on Wednesday, October 4th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company. Adamas Pharmaceuticals has an average rating of “Buy” and a consensus price target of $44.86.

Institutional investors and hedge funds have recently made changes to their positions in the company. Citadel Advisors LLC acquired a new stake in shares of Adamas Pharmaceuticals in the 2nd quarter valued at $606,000. Granite Point Capital Management L.P. raised its holdings in shares of Adamas Pharmaceuticals by 11.9% in the 2nd quarter. Granite Point Capital Management L.P. now owns 263,515 shares of the specialty pharmaceutical company’s stock valued at $4,609,000 after purchasing an additional 28,000 shares in the last quarter. Hikari Power Ltd acquired a new stake in shares of Adamas Pharmaceuticals in the 3rd quarter valued at $635,000. EAM Investors LLC acquired a new stake in shares of Adamas Pharmaceuticals in the 3rd quarter valued at $1,795,000. Finally, Vanguard Group Inc. raised its holdings in shares of Adamas Pharmaceuticals by 4.0% in the 2nd quarter. Vanguard Group Inc. now owns 745,237 shares of the specialty pharmaceutical company’s stock valued at $13,034,000 after purchasing an additional 28,818 shares in the last quarter. Institutional investors and hedge funds own 79.40% of the company’s stock.

Shares of Adamas Pharmaceuticals (ADMS) opened at $35.61 on Friday. Adamas Pharmaceuticals has a fifty-two week low of $13.50 and a fifty-two week high of $38.22. The firm has a market cap of $811.16, a price-to-earnings ratio of -10.60 and a beta of 1.13. The company has a debt-to-equity ratio of 0.41, a current ratio of 8.35 and a quick ratio of 8.32.

Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings data on Thursday, November 2nd. The specialty pharmaceutical company reported ($1.04) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.01) by ($0.03). During the same quarter last year, the business posted ($0.66) EPS. Adamas Pharmaceuticals’s revenue was down 99.3% compared to the same quarter last year. sell-side analysts anticipate that Adamas Pharmaceuticals will post -3.84 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Adamas Pharmaceuticals Sees Unusually Large Options Volume (ADMS)” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/12/adamas-pharmaceuticals-sees-unusually-large-options-volume-adms.html.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.